News for CSL Limited (CSLLY)

Revenue (FY 2024): $152.3 million, a decrease from $166.8 million in 2023.Revenue (Q4 2024): $22.8 million, down from $30.9 million in Q4 2023.Net Loss (FY 202

”“ Esperion to Receive an Upfront Payment and Near-Term Milestones Along with a Profitable Transfer Price on Product Sales ”“ ANN ARBOR, Mich., March 03, 2

Arcturus Therapeutics Holdings Inc. (the ”œCompany”, ”œArcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development

PR NewswireWALTHAM, Mass. and SAN DIEGO, Feb. 14, 2025 - KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immuno

Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced that the European Commission

Takeda’s plasma-derived therapies (PDT) business tackles supply-chain challenges to expand access to life-saving treatments, a key revenue driver at $5.85B in 2023.

Billionaire investor Warren Buffett's firm invests in Australian companies CSL, Life360, and WiseTech in a strategic financial move.

The following slide deck was published by CSL Limited in conjunction with their 2025 Q2 earnings call.

CSL Limited (OTCQX:CSLLY) Q2 2025 Results Earnings Conference Call February 10, 2025 7:00 PM ETCompany ParticipantsChris Cooper - Vice President and Head of...

CSL Ltd has reported rises in profit and revenue for the first half of the 2025 fiscal year, with particular growth in its CSL Behring arm

Arcturus Therapeutics Holdings Inc. (the ”œCompany”, ”œArcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development

Arcturus Therapeutics Holdings Inc. (the ”œCompany”, ”œArcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development

Establishing sepsis diagnostic InfectID™ as the new standard of care

Arcturus Therapeutics Holdings Inc. (the ”œCompany”, ”œArcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development

Welcome to the end of another week. Let's start with what HotCopper users have been watching and discussing.

Arcturus Therapeutics to Present at Jefferies London Healthcare Conference

Earnings call: Amarin reports Q3 revenue dip amid U.S. generic competition

Riverside sells PFB units to Carlisle for $260 million

The Needle-Free Injector Market is growing rapidly along with the escalating requirements of pain-free drug delivery systems, greater needle-phobic...